NASDAQ: VBIV - VBI Vaccines Inc.

Yield per half year: 0%
Dividend yield: 0.00%
Sector: Healthcare

Share chart VBI Vaccines Inc.

Extended chart Simple chart
Financial Markets by TradingView

About VBI Vaccines Inc.

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.

more details
In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 1995-08-18
ISIN CA91822J1030
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Дивиденд ао 0.25
Сайт https://www.vbivaccines.com
Цена ао 0.0282
Change price per day: 0% (0.0282)
Change price per week: 0% (0.0282)
Change price per month: 0% (0.0282)
Change price per 3 month: 0% (0.0282)
Change price per half year: 0% (0.0282)
Change price per year: -95.14% (0.58)
Change price per 3 year: -98.34% (1.7)
Change price per 5 year: -96.14% (0.7307)
Change price per year to date: 0% (0.0282)
All parameters

Underestimation

Title Value Grade
P/S 0.9865 9
P/BV 1.14 9
P/E 0 0
EV/EBITDA -0.7112 0
Total: 6

Efficiency

Title Value Grade
ROA, % -106.77 0
ROE, % -1233.37 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0.7 7
Total: 1.16

Debt

Title Value Grade
Debt/EBITDA -0.9947 10
Total: 7.8

Growth impulse

Title Value Grade
Yield Revenue, % 294.64 10
Yield Ebitda, % 15.66 3
Yield EPS, % -60.52 0
Total: 4.6
More

Institutions Volume Share, %
Perceptive Advisors LLC 1381355 5.83
Alyeska Investment Group, L.P. 696736 2.94
Geode Capital Management, LLC 138729 0.59
Blackrock Inc. 111960 0.47
Cambridge Investment Research Advisors Inc. 93556 0.39
Millennium Management LLC 71422 0.3
Vanguard Group Inc 64522 0.27
General American Investors Company Inc 62583 0.26
Morgan Stanley 34973 0.15
Northern Trust Corporation 32992 0.14



Head Job title Payment Year of birth
Mr. Jeffery R. Baxter FCMA President, CEO & Director 908.06k 1961 (64 years)
Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D. Chief Medical Officer 544.52k 1955 (70 years)
Ms. Nell Beattie CFO, Head of Corporate Development & Director N/A 1988 (37 years)
Ms. Athena Kartsaklis Senior VP of Finance, Chief Compliance Officer & Principal Financial Officer N/A 1965 (60 years)
Mr. Avi Mazaltov Global Head of Manufacturing & GM of SciVac N/A 1962 (63 years)
Mr. Misha Nossov Senior VP of Global Commercial Supply Strategy & Head of Europe N/A
Mr. John Robert Dillman Chief Commercial Officer N/A 1968 (57 years)
Dr. David Evander Anderson Ph.D. Chief Scientific Officer 1970 (55 years)
Ms. Nicole Anderson Director of Corporate Communications & Investor Relations
Mr. T. Adam Buckley B.Sc., MBA Senior Vice President of Business Development 1976 (49 years)

Address: United States, Cambridge. MA, 160 Second Street - open in Google maps, open in Yandex maps
Website: https://www.vbivaccines.com